Quick Answer
Artiva Biotherapeutics, Inc. reported Net Income of -$83.86 million for fiscal year 2025.
Artiva Biotherapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$83.86M | -28.3% |
| 2024 | -$65.37M | -127.6% |
| 2023 | -$28.72M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$21.53M | -23.2% | -1.3% |
| June 30, 2025 | -$21.25M | -19.1% | -4.6% |
| March 31, 2025 | -$20.31M | -45.5% | -16.2% |
| September 30, 2024 | -$17.47M | -254.9% | +2.1% |
| June 30, 2024 | -$17.84M | -58.1% | -27.8% |
| March 31, 2024 | -$13.96M | +16.5% | -223.8% |
| September 30, 2023 | $11.28M | — | +200.0% |
| June 30, 2023 | -$11.28M | — | +32.5% |
- Artiva Biotherapeutics, Inc. showed a decrease of -28.3% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Artiva Biotherapeutics, Inc.’s net income has declined by 192.0% (from -$28.72 million to -$83.86 million).
- The most recent figure is from Artiva Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: